Hepatic fibrosis represents a significant challenge in the management of chronic liver diseases, with its progression often leading to cirrhosis and liver failure. Traditional methods for assessing hepatic fibrosis, such as liver biopsy, are invasive and carry risks. Consequently, there has been considerable interest in developing non-invasive techniques for evaluating hepatic fibrosis. In recent years, significant advancements have been made in this field, offering clinicians a range of non-invasive tools for accurately assessing fibrosis progression and guiding treatment decisions. This review highlights the latest advancements in non-invasive techniques for hepatic fibrosis assessment and their clinical implications. We discuss the utility of various imaging modalities, including transient electrography, magnetic resonance elastography, and ultrasound-based techniques, in accurately quantifying liver stiffness and detecting fibrosis. Additionally, we examine the role of serum biomarkers, such as Fibrosis-4 index (FIB-4), Aspartate Aminotransferase to Platelet Ratio Index (APRI) and Enhanced Liver Fibrosis (ELF) panel, in predicting fibrosis severity and monitoring disease progression.
HTML PDFShare this article
Hepatology and Pancreatic Science received 34 citations as per Google Scholar report
